Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis

被引:3
|
作者
Guo, Yinxue [1 ]
Ge, Pingyu [2 ]
Li, Ziju [1 ]
Xiao, Jingxia [1 ]
Xie, Lirui [1 ]
机构
[1] Guizhou Univ Tradit Chinese Med, Dept Nephrol, Affiliated Hosp 1, Guiyang 550001, Guizhou, Peoples R China
[2] Guizhou Univ Tradit Chinese Med, Dept Urol, Affiliated Hosp 1, Guiyang 550001, Guizhou, Peoples R China
关键词
ACUTE CORONARY SYNDROMES; PLATELET INHIBITION; ASIAN PATIENTS; OUTCOMES; THERAPY; BURDEN; DEATH; CKD;
D O I
10.1007/s40256-023-00600-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The worldwide prevalence of chronic kidney disease (CKD) has significantly increased in the past decades. Scientific reports have shown CKD to be an enhancing risk factor for the development of cardiovascular disease (CVD), which is the leading cause of premature death in patients with CKD. Clinical practice guidelines are ambiguous in view of the use of antiplatelet drugs in patients with CKD because patients with moderate-to-severe CKD were often excluded from clinical trials evaluating the efficacy and safety of anticoagulants and antiplatelet agents. In this analysis, we aimed to systematically assess the adverse cardiovascular and bleeding outcomes that were observed with ticagrelor versus clopidogrel use in patients with CKD and cardiovascular disease.Methods Electronic databases including Web of Science, Google Scholar, , Cochrane database, EMBASE, and MEDLINE were carefully searched for English-based articles comparing ticagrelor with clopidogrel in patients with CKD. Adverse cardiovascular outcomes and bleeding events were the endpoints in this study. The latest version of the RevMan software (version 5.4) was used to analyze the data. Risk ratios (RR) with 95% confidence intervals (CI) were used to represent the data post analysis.ResultsA total of 15,664 participants were included in this analysis, whereby 2456 CKD participants were assigned to ticagrelor and 13,208 CKD participants were assigned to clopidogrel. Our current analysis showed that major adverse cardiac events (MACEs) (RR: 0.85, 95% CI: 0.71-1.03; P = 0.09), all-cause mortality (RR: 0.82, 95% CI: 0.57- 1.18; P = 0.29), cardiovascular death (RR: 0.83, 95% CI: 0.56-1.23; P = 0.35), myocardial infarction (RR: 0.87, 95% CI: 0.70-1.07; P = 0.19), ischemic stroke (RR: 0.80, 95% CI: 0.58-1.11; P = 0.18), and hemorrhagic stroke (RR: 1.06, 95% CI: 0.38-2.99; P = 0.91) were not significantly different in CKD patients who were treated with ticagrelor versus clopidogrel. Thrombolysis in myocardial infarction (TIMI)-defined minor (RR: 0.89, 95% CI: 0.52-1.53; P = 0.68) and TIMI major bleeding (RR: 1.10, 95% CI: 0.69-1.76; P = 0.67) were also not significantly different. However, bleeding defined according to the academic research consortium (BARC) bleeding type 1 or 2 (RR: 1.95, 95% CI: 1.13-3.37; P = 0.02) and BARC bleeding type 3 or 5 (RR: 1.70, 95% CI: 1.17-2.48; P = 0.006) were significantly higher with ticagrelor.Conclusions When compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
引用
收藏
页码:533 / 546
页数:14
相关论文
共 50 条
  • [31] Cardiovascular disease in patients with coeliac disease: A systematic review and meta-analysis
    Emilsson, Louise
    Lebwohl, Benjamin
    Sundstrom, Johan
    Ludvigsson, Jonas F.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 (10) : 847 - 852
  • [32] Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis
    Major, Rupert W.
    Oozeerally, Issaam
    Dawson, Simon
    Riddleston, Helen
    Gray, Laura J.
    Brunskill, Nigel J.
    ATHEROSCLEROSIS, 2016, 251 : 177 - 182
  • [33] Chronic Kidney Disease in Inflammatory Bowel Disease: a Systematic Review and Meta-analysis
    Zadora, Ward
    Innocenti, Tommaso
    Verstockt, Bram
    Meijers, Bjorn
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (09) : 1464 - 1475
  • [34] New antiplatelet agents for cardiovascular disease
    Chua, Doson
    Nishi, Cesilia
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (16) : 1405 - 1411
  • [35] Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
    Wang, Zhe
    Zhou, Da-Yan
    Su, Yong
    Si, Liang-Yi
    Xu, Qiang
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)
  • [36] Antiplatelet effects of aspirin in chronic kidney disease patients
    Polzin, A.
    Dannenberg, L.
    Sansone, R.
    Levkau, B.
    Kelm, M.
    Hohlfeld, T.
    Zeus, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (02) : 375 - 380
  • [37] Efficacy and Safety of Veverimer in the Treatment of Metabolic Acidosis Caused by Chronic Kidney Disease: A Meta-analysis
    Liu, Wenlin
    Li, Lili
    Zhang, Xuemei
    Dong, Haonan
    Lu, Miaomiao
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] Ticagrelor or Aspirin After Coronary Artery Bypass in Patients With Chronic Kidney Disease
    Sandner, Sigrid E.
    Schunkert, Heribert
    Kastrati, Adnan
    Milojevic, Milan
    Boning, Andreas
    Zimpfer, Daniel
    Zellmer, Stephan
    Wiedemann, Dominik
    Laufer, Gunther
    von Scheidt, Moritz
    ANNALS OF THORACIC SURGERY, 2022, 113 (02) : 554 - 562
  • [39] Efficacy and Safety of Tanshinone for Chronic Kidney Disease: A Meta-Analysis
    Zhou, Yao
    Jiang, Shi-min
    Li, Li
    Wang, Ying
    Ding, Lei
    Liu, Chao-xia
    Wu, Qi
    Gao, Kun
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
  • [40] The Effect of Ketoanalogues on Chronic Kidney Disease Deterioration: A Meta-Analysis
    Li, Albert
    Lee, Hsiang-Yen
    Lin, Yen-Chung
    NUTRIENTS, 2019, 11 (05)